AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-914-8420
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Avrobio (NASDAQ:AVRO) Frequently Asked Questions
What is Avrobio's stock symbol?
Avrobio trades on the NASDAQ under the ticker symbol "AVRO."
How were Avrobio's earnings last quarter?
Avrobio Inc (NASDAQ:AVRO) posted its earnings results on Thursday, August, 8th. The company reported ($0.67) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.76) by $0.09. View Avrobio's Earnings History.
When is Avrobio's next earnings date?
What price target have analysts set for AVRO?
7 brokers have issued 12-month price objectives for Avrobio's stock. Their forecasts range from $19.00 to $43.00. On average, they anticipate Avrobio's share price to reach $29.8840 in the next twelve months. This suggests a possible upside of 58.6% from the stock's current price. View Analyst Price Targets for Avrobio.
What is the consensus analysts' recommendation for Avrobio?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.
What are Wall Street analysts saying about Avrobio stock?
Here are some recent quotes from research analysts about Avrobio stock:
- 1. According to Zacks Investment Research, "Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States. " (7/23/2019)
- 2. HC Wainwright analysts commented, "Our $40 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF analysis, which is based on: beta of 1.15, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.5%, and tax rate of 15% beginning in FY 2028. Our price target reflects uncertainties stemming from the clinical update from the Fabry program (AVR-RD-01), resulting in: (1) a push out of our launch estimate into 2H-2022, vs. prior 2H-2021; and (2) lower Fabry POS of 25% from 30%." (1/15/2019)
Has Avrobio been receiving favorable news coverage?
Media coverage about AVRO stock has trended positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avrobio earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Avrobio.
Are investors shorting Avrobio?
Avrobio saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 991,600 shares, an increase of 17.9% from the June 30th total of 841,200 shares. Based on an average trading volume of 321,800 shares, the short-interest ratio is presently 3.1 days. Approximately 7.5% of the shares of the stock are sold short. View Avrobio's Current Options Chain.
Who are some of Avrobio's key competitors?
Some companies that are related to Avrobio include Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS), Sangamo Therapeutics (SGMO), Regenxbio (RGNX), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Orchard Therapeutics (ORTX), Aerie Pharmaceuticals (AERI), Alector (ALEC), NanoString Technologies (NSTG), Twist Bioscience (TWST), Rubius Therapeutics (RUBY) and BAVARIAN NORDIC/S (BVNRY).
What other stocks do shareholders of Avrobio own?
Who are Avrobio's key executives?
Avrobio's management team includes the folowing people:
- Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 53)
- Mr. Steven N. Avruch, VP, Gen. Counsel & Sec. (Age 58)
- Mr. Jeffrey Medin Ph.D., Scientific Founder
- Mr. Erik Ostrowski, CFO & Treasurer (Age 46)
- Dr. Kim Warren, Head of Operations
When did Avrobio IPO?
(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.
Who are Avrobio's major shareholders?
Avrobio's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (6.65%), Blackstone Group Inc (6.13%), JPMorgan Chase & Co. (6.00%), BlackRock Inc. (5.06%), Farallon Capital Management LLC (4.29%) and Price T Rowe Associates Inc. MD (3.35%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View Institutional Ownership Trends for Avrobio.
Which major investors are selling Avrobio stock?
AVRO stock was sold by a variety of institutional investors in the last quarter, including Blackstone Group Inc, Orbimed Advisors LLC, Cormorant Asset Management LP, Victory Capital Management Inc., Emerald Advisers LLC, Artal Group S.A., Citadel Advisors LLC and Swiss National Bank. Company insiders that have sold Avrobio company stock in the last year include Christopher Paige and Geoffrey Mackay. View Insider Buying and Selling for Avrobio.
Which major investors are buying Avrobio stock?
AVRO stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Price T Rowe Associates Inc. MD, BlackRock Inc., AlpInvest Partners B.V., Farallon Capital Management LLC, Vanguard Group Inc., Granite Point Capital Management L.P. and Bessemer Group Inc.. View Insider Buying and Selling for Avrobio.
How do I buy shares of Avrobio?
Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avrobio's stock price today?
One share of AVRO stock can currently be purchased for approximately $18.84.
How big of a company is Avrobio?
Avrobio has a market capitalization of $454.93 million. The company earns $-46,360,000.00 in net income (profit) each year or ($3.62) on an earnings per share basis. Avrobio employs 49 workers across the globe.View Additional Information About Avrobio.
What is Avrobio's official website?
How can I contact Avrobio?
Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]
MarketBeat Community Rating for Avrobio (NASDAQ AVRO)
MarketBeat's community ratings are surveys of what our community members think about Avrobio and other stocks. Vote "Outperform" if you believe AVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
